Archives

TFS International acquires Beardsworth Consulting

Monday, May 6, 2013 11:37 AM

In a move to expand its oncology and vaccine research services, TFS International, a full service CRO, has completed the acquisition of Beardsworth Consulting Group (BCG), a New Jersey-based oncology and vaccine specialist CRO.

More... »

Novotech attracts investment for Asian clinical trial expansion

Monday, May 6, 2013 11:08 AM

Novotech, an Australia-based independent CRO, received a funding injection from private equity firm Mercury Capital.

More... »

AltheRx raises $15M, names Jim Bennethum CEO, appoints new board of directors

Monday, May 6, 2013 10:41 AM

AltheRx Pharmaceuticals, a privately-held clinical development company, announced a restructuring that includes a $15 million financing, the appointment of Jim Bennethum as CEO, and the appointment of a new board of directors.

More... »

Ambrx, BMS collaborate on next-gen antibody drug conjugates

Monday, May 6, 2013 10:09 AM

Ambrx, a clinical stage biopharmaceutical company, entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

More... »

Raptor Pharma's Procysbi receives FDA approval for nephropathic cystinosis

Friday, May 3, 2013 02:02 PM

The FDA has approved Raptor Pharmaceutical’s Procysbi(cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children six years and older.

More... »

Sanofi appoints two new members to executive committee

Friday, May 3, 2013 12:22 PM

Global healthcare company Sanofi is creating two new units, global commercial operations and global divisions and strategic commercial development, to replace the former global operations unit. Peter Guenter, currently senior vice president, Europe, will be appointed executive vice president of global commercial operations. Pascale Witz, currently president and CEO of medical diagnostics at GE Healthcare, will join Sanofi as executive vice president of global divisions and strategic commercial development. Both Guenter and Witz will join the executive committee.

More... »

FDA grants Genmab’s daratumumab Breakthrough Therapy Designation

Friday, May 3, 2013 11:55 AM

The FDA has granted Breakthrough Therapy Designation for Genmab’s daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and IMiD. 

More... »

Bio-Optronics, Schulman Associates IRB to simplify clinical trial management

Friday, May 3, 2013 11:30 AM

Bio-Optronics, a software and services provider, and Schulman Associates IRB, an international, AAHRPP-accredited independent IRB, announced their partnership and their newly integrated regulatory compliance module for the Clinical Conductor Enterprise CTMS application. This collaboration offers Clinical Conductor Enterprise CTMS users streamlined IRB interactions from one centralized location.

More... »

Soligenix, Intrexon pursue melioidosis therapy through exclusive collaboration

Friday, May 3, 2013 10:48 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, will jointly develop a treatment for melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.

More... »

Abide Therapeutics, Merck to develop novel therapies for T2D, metabolic diseases

Friday, May 3, 2013 10:19 AM

Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, has entered into a collaboration agreement with Merck, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

More... »